
UCB names next chief executive
pharmafile | February 25, 2014 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | UCB, tellier
Biopharma firm UCB has confirmed its current chief executive Roch Doliveux is to be replaced by Jean-Christophe Tellier.
Tellier (pictured) who is currently the firm’s executive VP of Biopharma Brands and Solutions, will be appointed chief executive-elect and chairman of the executive committee from March this year.
Doliveux still remains chief executive of UCB until next year, but as 2015 begins Tellier will take over this role indefinitely.
Gerhard Mayr, chairman of UCB’s board of directors, said: “We are confident that Jean-Christophe Tellier will continue to drive UCB to provide superior and sustainable value for patients. He and Roch will continue to work together throughout 2014 to ensure a smooth handover before Jean-Christophe takes the helm of UCB as of 1 January, 2015.”
Doliveux added that Tellier’s 25-year career in the biopharma industry, his patient-centric approach, his medical background as a rheumatologist and his passion for developing talent make him the perfect candidate to lead the company through its next phase.
“We are fortunate to have found UCB’s future leader internally; it has been a privilege for me to work with the board to identify and develop my successor,” he said.
Related Content

UCB presents positive results for fenfluramine in CDKL5 deficiency disorder
UCB has announced positive results from its phase 3 GEMZ study, showing that fenfluramine can …

UCB announces first-in-patient trial success for galvokimig in atopic dermatitis
UCB has reported positive early clinical trial results for galvokimig, an investigational therapy for adults …

Rare and severe epilepsies – current treatments and advance therapeutics
The current forms of immunotherapy, how T cell therapy works and what the future holds






